Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
RESEARCH TOOLSreports
KYMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.24 - $53.27
Previous CloseN/A
Volume48.51K
Average Volume (3M)499.57K
Market Cap
$2.39B
Enterprise Value$3.14B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Feb 20, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding64,765,274
10 Day Avg. Volume470,245
30 Day Avg. Volume499,568
Standard Deviation0.24
R-Squared0.19
Alpha0.00567
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.28
Price to Cash Flow (P/CF)-11.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-28.43
Enterprise Value/Ebitda-19.52
Forecast
1Y Price Target
$60.38Price Target Upside60.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Kymera Therapeutics News
PremiumPre-Earnings
Is KYMR a Buy, Before Earnings?
PremiumCompany Announcements
Kymera Therapeutics Unveils 2025 Strategy and Trials
---
Bulls Say, Bears Say
Bulls Say
Development PipelineKymera aims to develop KT-621 in at least all of the indications where Dupixent is currently approved, with plans to begin multiple studies to enable an efficient and broad late-stage development effort.
Financial StabilityKYMR has a busy 2025 and 2026 ahead and is well-capitalized through these next development steps.
Strategic InterestJNJ's in-licensing of an oral STAT6 program demonstrates continued strategic interest in this target, which is seen as a positive for KYMR, which recently started a Phase 1 for STAT6 degrader KT-621.
Bears Say
Development ChallengesIf KT-621 early development is challenged by poor drug properties or unexpected toxicity there is significant downside potential for KYMR.
Market CompetitionKT-621 is unlikely to outperform JAK inhibitors or dupilumab, which provide a broader and more effective blockade of allergic inflammation.
Risk/Benefit ProfileUncertainty exists about the long-term risk/benefit profile of degrading targets to justify revenues that provide upside to KYMR's current valuation.
---
Ownership Overview
28.27% Insiders
30.51% Mutual Funds
0.06% Other Institutional Investors
28.02% Public Companies and Individual Investors
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $29.24 and its highest was $53.27 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $2.39B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.832 by $0.012.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -0.78.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 64,765,274 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.832. Following the earnings report the stock price went down -3.147%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
---
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.38 (60.37% Upside)
$60.38 (60.37% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.85%
12-Months-Change
Fundamentals
Return on Equity
-18.76%
Trailing 12-Months
Asset Growth
87.34%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
---
KYMR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in Kymera's immunology pipeline with the initiation of KT-621's Phase 1 study and the advancement of KT-474 to Phase 2b. Financially, the company is well-positioned with substantial cash reserves. However, strategic shifts in oncology programs and extended timelines for KT-474 Phase 2 trials were noted as challenges.Read More>---
KYMR Stock 12 Month Forecast
Average Price Target
$60.38
▲(60.37% Upside)
Technical Analysis
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Arvinas Holding Company
―
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+41.05%
reiterated a buy rating 4 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +41.05% per trade.
---